Pharmacokinetics of Etilevodopa Compared to Levodopa in Patient's with Parkinson's Disease: An Open-label, Randomized, Crossover Study

Clinical Neuropharmacology

Volumn 26, Issue 6, 2003, Pages 322-326

  Djaldetti, Ruth ^a   Giladi, Nir ^b   Hassin Baer, Sharon ^b   Shabtai, Hertzel ^b   Melamed, Eldad ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Etilevodopa; Motor fluctuations; Pharmacokinetics

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; ETILEVODOPA; LEVODOPA; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSTONIA; HEART PALPITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; TABLET; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; ELECTROCHEMISTRY; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TABLETS;

EID: 0344738870     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200311000-00012     Document Type: Article

References (16)

1. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2001;8:101-108.
2. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part I. Ann Neurol. 1988;24:366-371.
3. Okereke CS. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson's disease patients experiencing motor fluctuations with levodopa. J Pharm Pharm Sci. 2002;5:146-161.
4. Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology. 1994;44:1287-1292.
5. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41:261-309.
6. Merims D, Djaldetti R, Melamed E. Waiting for 'on' -a major problem in patients with Parkinson's disease and 'on-off' motor fluctuations. Clin Neuropharmacol. 2003;(in press)
7. Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature. 1973;242:463-465.
8. Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology. 1996;46:1051-1054.
9. Hardoff R, Tamir A, Sula M, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord. 2001;16: 104-107.
10. Robertson DR, Renwick AG, Wood ND, et al. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol. 1990; 29:47-53.
11. Djaldetti R, Ziv I, Melamed E. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Isr J Med Sci. 1996;32:1224-1227.
12. Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol. 1996;39:400-404.
13. Blaugrund E, Myke A, Sayag N, et al. Intestinal hydrolysis of TV-1203, a levodopa prodrug. Parkinsonism Relat Disorder. 1999;5: S67. (Abstract)
14. Djaldetti R, Inzelberg R, Giladi N, et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord. 2002;17:297-302.
15. Kelly MA. Motility of the stomach and gastroduodenal function. In: Johnson IR, ed. Physiology of the gastrointestinal tract. New York: Raven Press, 1981: 393-410.
16. Hardie RJ, Malcolm SL, Lees AJ, et al. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol. 1986;22:429-436.